Pages - Menu

▼

Monday, November 9, 2026

Gene Editing Delivery: Why Virus-Like Particles Matter Now

Credit: Feng Zhang

 

The scissors are ready, the courier is not

For years the big question in gene editing was whether we could cut DNA precisely. We can. CRISPR-Cas9, base editors and prime editors are real tools that work in real cells, and the first CRISPR medicine is already approved. So the question has quietly changed into something less glamorous: how do we get these tools into the right tissue of a human body?

It matters because most diseases misbehave in one particular tissue. A liver problem needs the editor in the liver. A blood disorder needs it in blood stem cells. An editor that lands in the wrong place does nothing useful at best, and causes trouble at worst. Cutting is the solved part. Delivery is where a lot of the field is stuck right now.

Take the cells out, or go inside the body?

The approved route is the easy one. Casgevy, from CRISPR Therapeutics and Vertex, treats sickle cell disease and transfusion-dependent beta-thalassemia. Doctors collect blood stem cells (CD34-positive cells) from the patient, and in the lab the Cas9 protein and its guide RNA are pushed into those cells with a short electric pulse called electroporation. The edited cells then go back to the patient. This is ex vivo editing, which simply means editing outside the body, and it works well because the cells sit in a dish where you control everything.

The price of that control is cost and complexity. You need a specialised hospital, a conditioning regimen, and a long stay. Hence the dream of in vivo editing: one injection in an ordinary clinic, and the patient's own tissue is reprogrammed. In parts of West Africa where sickle cell disease is common, the gap between a specialised transplant centre and a local clinic is not a technicality. It decides who can be treated at all.

A quick tour of the delivery vehicles

AAV. Adeno-associated virus is the workhorse of gene therapy, and its problem is room. It carries only about 4.7 kilobases of DNA, and a Cas9 gene plus a guide RNA plus the control elements to run them usually overshoots that. AAV DNA also sits in the nucleus as an episome, a small ring of DNA separate from your chromosomes. It is stable, and it only fades as cells divide. For a nuclease that is the wrong rhythm, because the longer Cas9 hangs around, the more chances it has to cut places it was never meant to cut.

Lentivirus. Lentiviral vectors hold roughly 8 to 10 kilobases, enough for editing tools, and they have a proven track record in CAR T cell therapies for blood cancers. The catch is that they integrate into your chromosomes. A scissors gene stitched into the genome keeps making scissors. Lentiviruses are usually given a borrowed coat protein in a process called pseudotyping, and the most popular coat, VSV-G, is about to become a main character.

Lipid nanoparticles (LNPs). These are tiny fat bubbles that carry RNA. Injected into the bloodstream, they pick up a protein called ApoE and are swallowed by liver cells through the LDL receptor route. The cargo then has to escape the endosome, the little bubble the cell wraps around anything it swallows, before it can do anything. That is why LNPs love the liver, and why getting them anywhere else is hard.

Intellia's nexiguran ziclumeran (nex-z) is the flagship example. It uses an LNP to deliver CRISPR components that switch off the TTR gene in the liver, as a one-time treatment for transthyretin amyloidosis. People sometimes call this a liver disease, but it is really a body-wide one: the liver is simply the factory that makes the misfolded protein.

It is also a useful reminder that liver delivery is not risk free. In October 2025 the FDA paused the nex-z phase 3 trials after a patient developed Grade 4 liver enzyme elevations and raised bilirubin, and later died. Intellia pointed to complicating comorbidities, and the holds were lifted in early 2026 with enhanced liver monitoring added. The lesson I take from it: a vehicle that goes to the liver by default is both a gift and a liability.

Why a short stay is a feature

The ideal editor does its job and leaves. You want a tight window in which the nuclease is active, enough to make the intended cut and not so long that it wanders. This is the real appeal of delivering the editor as a protein rather than as a gene. A protein is already working the moment it arrives, and the cell breaks it down within a short time. No DNA means nothing to integrate and nothing to keep expressing.

How do you deliver a protein to a cell without a gene? That is where virus-like particles come in.

Enter the virus-like particle

A virus-like particle (VLP) is a virus shell with the dangerous parts removed. It keeps the outer membrane and the structural proteins that let a virus dock, enter a cell and release its cargo, but it carries no viral genome, so it cannot replicate or integrate. Picture a delivery van wearing a courier's uniform: it knows how to find the right door and hand over the parcel, but it has no way of building new vans.

The engineering in David Liu's lab turned this into something practical. In their engineered VLPs (eVLPs), the editor protein is fused to a retroviral structural protein called Gag. When the particle assembles and buds out of a producer cell, it traps the editor together with its guide RNA as a ready-made ribonucleoprotein, or RNP, which is just the protein and RNA already bound to each other. A built-in protease then cuts the editor free inside the particle. In the 2022 Cell paper, eVLPs delivering a base editor achieved about 63% editing of the Pcsk9 gene in mouse liver, and a single injection partially restored vision in a mouse model of Leber congenital amaurosis.

So a VLP borrows from both worlds. It has the viral talent for getting into cells and releasing cargo, and the LNP-like virtue of leaving no genetic footprint.

The coat decides the address

The protein on the surface of the particle decides which cells it can enter. VSV-G (vesicular stomatitis virus glycoprotein) is a favourite because it is superb at binding cells and triggering fusion with the endosome. But its tropism, meaning the range of cells it can enter, is very broad. That is brilliant in a lab dish and a headache in medicine, where you want a particle that goes to a chosen cell and not everywhere.

The fix is a two-step trick. First, mutate VSV-G so that it no longer binds its natural receptors while keeping its ability to fuse, giving a version called VSVGmut. Second, display an antibody fragment on the particle surface, a single-chain variable fragment (scFv), to supply the address. The glycoprotein opens the door, and the antibody fragment tells the particle which door to knock on.

Jennifer Doudna's group, with Jennifer Hamilton as first author, built on this idea with enveloped delivery vehicles (EDVs). In a culture test with a mix of cells that did and did not carry the B cell marker CD19, CD19-targeted EDVs carrying Cas9 knocked out the B2M gene in up to 74% of target cells, with little to no editing in bystander cells. In mice with a humanised immune system, EDVs went on to generate gene-edited CAR T cells in vivo, with no off-target delivery to liver hepatocytes. That last detail is what caught my eye, because the liver is exactly where most delivery vehicles end up. Hamilton and Doudna later co-founded Azalea Therapeutics, whose lead program is a CD19-targeted in vivo CAR T therapy heading toward the clinic.

Where do VLPs stand in the clinic?

As of November 2026, and to my knowledge, no VLP-delivered nuclease or base editor has been given to a patient. The closest example is Ensoma's EN-374, which uses VLPs to deliver a working copy of the CYBB gene to blood stem cells inside the body, for X-linked chronic granulomatous disease. That is gene addition rather than gene editing, but it is billed as the first in vivo blood stem cell gene insertion therapy in the clinic, and the first participant's safety data were presented in May 2026. If it stays safe, it tells regulators something useful about VLPs in general.

An old idea with a new job

VLPs were doing medicine long before CRISPR. The hepatitis B vaccine, licensed in 1986, is built from hepatitis B surface antigen that assembles into virus-like particles with no genome inside, and the HPV vaccines later followed the same logic. The immune system sees a convincing virus shape, builds memory, and nothing infectious was ever in the vial. What is new is not the particle. It is the idea of loading it with an editor and putting an address label on the outside.

What I am watching

I like this story because it is gloriously unfinished. Much of the current work is careful tinkering: the linkers that hold the antibody fragment on the surface, the glycoprotein mutations, the way the editor is packed inside. Three things will tell us whether VLPs grow up. First, clinical data from a VLP-delivered editor. Second, whether the targeting holds up in larger animals and not just mice. Third, whether production, which relies on transfected producer cells much like lentiviral manufacturing, can scale.

If they do, the next question will not be whether we can edit a gene, but which cell we choose to send the courier to.

Watch the video

This post is adapted from the third video in Kevin Curran's gene editing delivery series, with corrections and updates built in: https://www.youtube.com/watch?v=97EpLp1Crf8

Related content

  • CRISPR-Cas9 basics: guide RNA, PAM and the sickle cell example
  • Specificity vs sensitivity in CRISPR diagnostics: cry wolf, miss wolf
  • Treatments that came from CRISPR

References

Banskota, S., Raguram, A., Suh, S., ... Liu, D. R. (2022). Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell, 185(2), 250-265.e16. https://doi.org/10.1016/j.cell.2021.12.021

Ensoma. (2026, May). Ensoma to present clinical safety data from first participant dosed with in vivo HSC engineering therapy at ASGCT Annual Meeting [Press release]. https://www.biospace.com/press-releases/ensoma-to-present-clinical-safety-data-from-first-participant-dosed-with-in-vivo-hsc-engineering-therapy-at-asgct-annual-meeting

Hamilton, J. R., Chen, E., Perez, B. S., Sandoval Espinoza, C. R., Kang, M. H., Trinidad, M., ... Doudna, J. A. (2024). In vivo human T cell engineering with enveloped delivery vehicles. Nature Biotechnology, 42(11), 1684-1692. https://doi.org/10.1038/s41587-023-02085-z

Intellia Therapeutics. (2026, January 27). Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN [Press release]. https://ir.intelliatx.com/node/12431

Intellia Therapeutics. (2026, March 2). Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM [Press release]. https://www.sec.gov/Archives/edgar/data/1652130/000119312526084309/d101756dex992.htm


No comments:

Post a Comment